Biologics In Focus

Biologics In Focus

Welcome to May’s ‘Biologics In Focus’, the monthly newsletter from Lonza Biologics. 

Each month we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories.

If you enjoy reading this month’s edition, why not subscribe to ensure you never miss an update?

Lonza News and Updates

Lonza and TriLink BioTechnologies collaboration

Lonza and TriLink Biotechnologies have announced a non-exclusive License and Supply Agreement that aims to drive greater access to CleanCap mRNA capping technologies as the demand for mRNA continues to grow. Read more here.

Insights and Analysis

Webinar: Addressing development challenges of new molecular formats

Next generation biological molecules are becoming increasingly prevalent in today’s biopharmaceutical manufacturing landscape and present unique developmental issues.

April’s webinar uses case studies to highlight innovative analytical strategies designed to address some of the most common challenges, such as multiple-MoAs, in process testing and throughput. Watch it on demand here.

Lonza in the Press

The benefits of partnering with a CDMO for Early Stage Development 

Dr Raymond Donninger and Dr James Berrie recently spoke with PHARMAnetwork magazine about how the expertise, efficiency and scalability of a CDMO can efficiently and cost-effectively help to deliver new therapeutic candidates for investigational new drug (IND) application and first-in-human (FIH) trials. Find the article here, pp24-27.

Accelerating your biotherapeutics’ path to clinic

In recent decades, many new biotherapeutics have undergone clinical trial testing, aiming to address unmet medical needs across various disease areas. However, the development timelines for these breakthrough molecules are often lengthy.

In this article, featured in Labiotech,  Andrew Brown and Alice Harrison discuss the role that tailored development strategies are playing in accelerating novel molecules into the clinic. Find out more here.

Customer Case Study

aTyr’s experience working with Lonza for its lead mAb candidate

In this article, aTyr discusses its selection of Lonza as CDMO and subsequent experience with the Ibex® Design program, which dispelled preconceived views about Lonza’s suitability for smaller biotechs. Read it here.


Upcoming Events

To meet with our team at BIO International, please contact us here


ESACT Session

June 25, 12.40: Industry perspectives on cell line development


Upcoming Webinars

Tuesday, June 4. 11am EDT | 5pm CET Register here

Deciphering mRNA immunogenicity: the what, why and how of early assessment

Thursday, June 6. 11am EDT | 5pm CET Register here

Advancing early-stage bispecific discovery programs towards clinical success, with GS Discovery® and bYlok® technology

Wednesday, June 12. 11am EDT | 5pm CET Register here

Navigating your holistic approach to container closure integrity for biologic drug products


Thank you for reading. Remember to subscribe so you never miss our monthly updates.

If you'd like to find out more about Lonza Biologics, you can visit our website here or contact one of our team of experts here



Snehashish Chakkravarty

CXO Relationship Manager AT BHARAT CXO

7mo

Thank you for sharing this information for useful

Like
Reply
Dimor Elbers

Associate Director Licensing at Lonza

7mo

Great newsletter! Big thanks to all involved! Excellent idea to have also the web links included for the upcoming webinars.

To view or add a comment, sign in

More articles by Lonza

Explore topics